RRMM

Challenges in treatment of RRMM

Hematologist, Oslo Myeloma Center, Department of Hematology, Norway

Challenges in Treating Relapsed/Refractory Multiple Myeloma

This e-learning has been developed by an international expert panel. The content will be offered through a mixture of theory, interactive questions, and challenging patient cases presented and discussed by international experts.

The e-learning will take approximately 3 hours of your time. You can pause and continue with the e-learning at any time.

It will provide you with useful insights that can support you in your daily clinical practice, especially when you are facing difficult treatment decisions for patients with relapsed/refractory multiple myeloma.

Module 1: Optimizing treatment sequencing in RRMM

Accredited for 1 CME point

Start module 1

Module 2: Treating challenging RRMM patient subgroups

Accredited for 1 CME point

Start module 2

Module 3: Treatment implications and quality of life

Accredited for 1 CME point

Start module 3

Scientific Expert Panel

MD, PhD Inger Nijhof

Hematologist,

St. Antonius Hospital,

Department of Internal Medicine,

The Netherlands

MD, PhD Fredrik Schjesvold

Hematologist,

Oslo Myeloma Center,

Department of Hematology,

Norway

MD, PhD Isabelle Vande Broek

Hematologist,

Vitaz, Sint-Niklaas,

Department of Oncology & Hematology,

Belgium

MD Agoston Gyula Szabo

Hematologist,

Righospitalet Copenhagen,

Department of Hematology,

Denmark

MD, PhD Ville Varmavuo

Chief Medical Officer in Education,

Kotka,

Internal Medicine,

Finland

MD, PhD Prof. Xavier Leleu

Hematologist,

Academic Hospital of Poitiers,

France

MD Valdas Peceliunas

Hematologist,

Vilnius University Hospital Santaros Klinikos,

Department of Hematology,

Lithuania

Share this e-learning with your colleagues
Accreditation

Accreditation for this e-learning has been granted for 1 point per module by:

European Accreditation Council for Continuing Medical Education (EACCME)

Obtain CME points

To obtain CME points, you must answer at least 70% of the questions in the final test correctly. If you have a lower score, you can retake the final test twice more. You can pause the e-learning and then resume where you paused.

Clinical cases

Throughout the e-learning challenging clinical cases from daily practice are being presented by the International Expert Panel.

See all clinical cases